icon-folder.gif   Conference Reports for NATAP  
 
  14th European AIDS Conference
Oct 16-19 2013
Brussels, Belgium
Back grey_arrow_rt.gif
 
 
 
Final Week 48 Analysis of Cenicriviroc (CVC) Compared to Efavirenz (EFV), in Combination with Emtricitabine/Tenofovir (FTC/TDF), in Treatment-Na´ve HIV-1-Infected Adults with CCR5-Tropic Virus (Study 652-2-202; NCT01338883)
 
 
  Reported by Jules Levin
EACS 2013 Oct 16-19 Brussels, Belgium
 
J. Feinberg1, M. Thompson2, J. Cade3, E. DeJesus4, J. Gathe5, J. Lalezari6, A. Scarsella7, M. Saag8, J. Enejosa9, E. Lefebvre9
1University of Cincinnati, Cincinnati, OH, USA, 2AIDS Research Consortium of Atlanta, Atlanta, GA, USA, 3Nevada AIDS Research and Education Society, Las Vegas, NV, USA, 4Orlando Immunology Center, Orlando, FL, USA, 5Therapeutic Concepts, Houston, TX, USA, 6Quest Clinical Research, San Francisco, CA, USA, 7Pacific Oaks Medical Group, Beverly Hills, CA, USA, 8University of Alabama at Birmingham, Birmingham, AL, USA, 9Tobira Therapeutics Inc., San Francisco, CA, USA

EACS1.gif

EACS2.gif

EACS3.gif

EACS4.gif

EACS5.gif

EACS6.gif

EACS7.gif

EACS8.gif

EACS9.gif

EACS10.gif

EACS11.gif

EACS12.gif